# Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis

> **NCT03006146** · PHASE1 · COMPLETED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 10 (actual)

## Conditions studied

- Autoimmune Pulmonary Alveolar Proteinosis

## Interventions

- **DRUG:** Sargramostim

## Key facts

- **NCT ID:** NCT03006146
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-13
- **Primary completion:** 2021-06-07
- **Final completion:** 2021-06-07
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-08-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03006146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03006146, "Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03006146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*